{
  "context": "\n<Summary source=\"https://www.statnews.com/2025/10/30/eli-lilly-zepbound-mounjaro-bestselling-obesity-drug/\">\n# Summary of Article: \"Eli Lilly's weight loss and diabetes drug tops Keytruda as world's best-selling medicine\"\n\n**Source:** STAT  \n**Date:** October 30, 2025  \n**Author:** Elaine Chen\n\n## Key Facts and Statistics:\n\n1. **Tirzepatide (Mounjaro/Zepbound) Sales Performance:**\n   - Q3 2025 sales: $10.1 billion\n   - Year-to-date sales (through Q3 2025): $24.8 billion\n   - Full-year 2025 analyst prediction (Visible Alpha): $32.2 billion\n\n2. **Keytruda (Merck) Sales for Comparison:**\n   - Q3 2025 sales: $8.1 billion\n   - Year-to-date sales (through Q3 2025): $23.3 billion\n   - Full-year 2025 analyst prediction (Visible Alpha): $31.8 billion\n\n3. **Eli Lilly Total Company Performance (Q3 2025):**\n   - Total revenue: $17.6 billion (exceeded analyst predictions of $16.1 billion)\n   - Updated full-year 2025 sales guidance: $63-63.5 billion (raised from previous $60-62 billion)\n   - Updated adjusted earnings per share guidance: $23.00-23.70 (raised from previous $21.75-23.00)\n\n4. **Approval Timeline:**\n   - Tirzepatide approved for diabetes: 2022\n   - Tirzepatide approved for obesity: 2024\n   - Keytruda became best-selling drug nine years after approval\n\n## Key Context:\n\n- Tirzepatide has now surpassed Keytruda as the world's best-selling medicine on a year-to-date basis\n- This is the second consecutive quarter where tirzepatide sales exceeded Keytruda on a quarterly basis\n- Lilly is viewed as having surpassed Novo Nordisk (maker of Ozempic and Wegovy) with a drug that can lead to even greater weight loss\n</Summary>\n\n<Summary source=\"https://www.biopharmadive.com/news/lilly-third-quarter-2025-earnings-zepbound-mounjaro-obesity-sales/804232/\">\n# Article Summary: Lilly hikes revenue forecasts on booming obesity drug sales\n\n**Source:** BioPharma Dive  \n**Date:** October 30, 2025  \n**Author:** Kristin Jensen\n\n## Key Facts and Statistics:\n\n1. **Q3 2025 Performance:**\n   - Tirzepatide (Zepbound for obesity + Mounjaro for diabetes) combined revenue: $10.1 billion in Q3 2025\n   - This represents an increase from $4.37 billion in Q3 2024\n   - Tirzepatide became the world's best-selling drug in Q3 2025, surpassing Merck's Keytruda ($8.1 billion)\n\n2. **Overall Q3 2025 Results:**\n   - Lilly's total Q3 revenue beat analyst expectations by 9%\n   - Earnings per share were 19% higher than consensus (according to Leerink Partners)\n\n3. **Updated Full-Year 2025 Forecasts:**\n   - Revenue: $63 billion to $63.5 billion (raised from previous $60-62 billion estimate)\n   - Earnings per share: $21.80 to $22.50 (raised from previous $20.85 to $22.10 estimate)\n\n## Market Context and Strategic Information:\n\n- Analysts expect the GLP-1 market to exceed $100 billion in the next decade\n- Lilly's stock price has remained relatively flat over the past 12 months despite strong Zepbound/Mounjaro sales\n- The company has faced challenges including sales occasionally falling short of high analyst expectations and revenue loss to compounders during manufacturing shortfalls\n- Lilly has shown Zepbound beat Novo's Wegovy in a head-to-head weight loss study\n- The company recently announced a deal with Walmart (mid-November implementation) to provide discounted drugs to customers\n- Lilly is investing heavily in production capacity for an experimental obesity pill before approval\n</Summary>\n\n<Summary source=\"https://www.prnewswire.com/news-releases/lilly-reports-third-quarter-2025-financial-results-highlights-rd-pipeline-momentum-and-raises-2025-guidance-302599148.html\">\n# Summary of Eli Lilly Q3 2025 Financial Results\n\n## Key Financial Metrics (Q3 2025):\n- **Worldwide revenue**: $17.60 billion (54% increase year-over-year)\n- **Revenue growth drivers**: 62% increase in volume, partially offset by 10% decrease due to lower realized prices\n- **U.S. revenue**: $11.30 billion (45% increase)\n- **Revenue outside U.S.**: $6.30 billion (74% increase)\n\n## Zepbound-Specific Results (Q3 2025):\n- **U.S. Zepbound revenue**: $3.57 billion (184% increase compared to Q3 2024's $1.26 billion)\n- **Primary driver**: Increased demand, partially offset by lower realized prices\n- **Note**: The article only reports U.S. revenue for Zepbound; no global/total revenue figure is provided for this product\n\n## Other Key Product Results (Q3 2025):\n- **Mounjaro worldwide revenue**: $6.52 billion (109% increase)\n  - U.S.: $3.55 billion (49% increase)\n  - Outside U.S.: $2.97 billion (compared to $728.0 million in Q3 2024)\n- **Key Products revenue** (defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound): $11.98 billion\n\n## Manufacturing and Pipeline Updates:\n- CEO David A. Ricks stated: \"We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico.\"\n- Orforglipron advanced through four additional Phase 3 trials, enabling global obesity submissions by year-end\n\n## Context for Forecasting:\nThis is Q3 2025 data. The question asks about Q1 2026 revenue, which would be reported approximately 6 months after this report. The article shows strong growth trajectory for Zepbound (184% YoY) but only provides U.S. revenue figures, not global totals.\n</Summary>\n\n<Summary source=\"https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html\">\n# Summary of Article: Eli Lilly Q4 2024 Earnings Report\n\n**Date:** February 6, 2025  \n**Source:** CNBC  \n**Author:** Annika Kim Constantino\n\n## Key Facts and Statistics:\n\n### Overall Q4 2024 Performance:\n- **Total Revenue:** $13.53 billion (up 45% year-over-year)\n- **Net Income:** $4.41 billion ($4.88 per share)\n- **Adjusted Earnings:** $5.32 per share (excluding one-time items)\n- **Result:** Earnings beat Wall Street estimates; sales fell slightly short\n\n### Zepbound (Tirzepatide) Performance:\n- **Q4 2024 Revenue:** $1.91 billion\n- **Analyst Expectations:** $1.98 billion (underperformed by ~$70 million)\n- **Notable Achievement:** Became market leader in obesity market in Q4 as measured by new prescriptions\n- **Context:** This was Zepbound's first full year on the U.S. market\n- **Pattern:** Underperformed expectations for two straight quarters\n\n### Mounjaro (Tirzepatide) Performance:\n- **Q4 2024 Revenue:** $3.53 billion (up 60% year-over-year)\n- **Analyst Expectations:** $3.62 billion (underperformed by ~$90 million)\n- **Revenue Impact:** Lower realized prices due to \"favorable changes\" in Q4 2023 estimates for rebates and discounts\n\n### 2025 Guidance:\n- **Fiscal 2025 Profit Guidance:** $22.05 to $23.55 per share (in line with analyst expectations)\n- **Fiscal 2025 Sales Guidance:** $58 billion to $61 billion (reiterated)\n- **Production Forecast:** At least 1.6 times the amount of incretin doses in first half of 2025 compared to first half of 2024\n\n## Opinions from Named Sources:\n\n**CFO Lucas Montarce (during earnings call):**\n- Expects \"a continuation of basically the total prescription growth that we have seen in 2024\" for incretin drugs such as Zepbound and Mounjaro\n- This expectation is built into the 2025 guidance\n\n## Additional Context:\n- Demand in the U.S. has far outpaced supply for incretin drugs over the last year\n- FDA declared the U.S. shortage of tirzepatide over in December 2024\n- Company previously pointed to inventory decreases among wholesalers as a factor in underperformance\n- Eli Lilly plans to launch Mounjaro in new international markets throughout 2025\n- Company shares rose more than 4% on the day of the earnings report\n</Summary>\n\n<Summary source=\"https://www.biospectrumasia.com/company-results/102/25588/eli-lilly-reports-record-q4-2024-revenue-of-13-53b-fueled-by-mounjaro-zepbound-and-oncology-growth.html\">\n# Summary of Article: Eli Lilly Q4 2024 Financial Results\n\n## Key Facts and Statistics Relevant to Zepbound:\n\n**Q4 2024 Zepbound Revenue:**\n- Zepbound generated **$1.2 billion in sales** during Q4 2024\n- The article describes this as following its U.S. FDA approval and launch, with \"rapid uptake\" highlighting growing demand for weight management solutions\n\n## Other Relevant Context:\n\n**Overall Company Performance (Q4 2024):**\n- Total revenue: $13.53 billion (45% increase)\n- Gross margin: 83.2%\n- R&D spending increased by 18%\n\n**Mounjaro Performance:**\n- Generated $3.5 billion in Q4 2024 sales (Mounjaro uses the same active ingredient as Zepbound - tirzepatide - but for Type 2 diabetes)\n\n**Zepbound Pipeline/Regulatory Developments:**\n- Received U.S. FDA approval as first prescription medication for moderate-to-severe obstructive sleep apnea in adults with obesity\n- Phase 3b SURMOUNT-5 study showed Zepbound delivered 47% greater weight loss compared to Wegovy\n- SUMMIT Phase 3 study of tirzepatide showed promising results in reducing risk of heart failure\n\n**Manufacturing and Strategic Developments:**\n- $3 billion manufacturing expansion in Wisconsin to enhance global production capabilities and meet growing demand\n- This expansion is expected to support production of key products across multiple therapeutic areas\n\n---\n\n**Note:** This article reports Q4 2024 results and does not contain information about Q1 2026 revenue projections or forecasts for Zepbound.\n</Summary>\n\n<Summary source=\"https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/37197042/heres-how-eli-lillys-oncology-drugs-are-poised-ahead-of-q4-earnings/\">\n# Summary of Article: \"Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings\"\n\n**Date:** January 23, 2026  \n**Source:** The Globe and Mail\n\n## Key Facts and Statistics:\n\n1. **Oncology Revenue Performance (First 9 Months of 2025):**\n   - Eli Lilly's oncology sales totaled $6.77 billion\n   - Year-over-year growth of approximately 9%\n   - Oncology accounted for around 15% of company's total revenue\n\n2. **Q4 2025 Expectations:**\n   - Zacks Consensus Estimate for oncology portfolio sales in Q4 2025: $2.64 billion\n   - Eli Lilly scheduled to report Q4 2025 earnings on February 4, 2026\n\n3. **Stock Performance:**\n   - Eli Lilly shares gained 35% in the past six months (compared to industry's 19.1% growth)\n   - Current forward P/E ratio: 32.02 (vs. industry average of 18.08)\n   - Trading below its five-year mean P/E of 34.56\n\n4. **Earnings Estimates:**\n   - 2025 earnings estimates: declined from $23.95 to $23.83 per share in past 60 days\n   - 2026 earnings estimates: improved from $33.36 to $33.41 per share over same timeframe\n\n## Key Product Information:\n\n- **Verzenio** (breast cancer drug): Expected to generate significant portion of oncology revenue\n- **Inluriyo** (imlunestrant): New breast cancer drug approved by FDA in late September 2025, launched in Q4 2025 in the U.S. - investors awaiting initial sales numbers\n- Other contributing drugs: Retevmo (RET inhibitor), Jaypirca (lymphoma drug)\n- Declining drugs: Alimta and Cyramza (facing competition from immuno-oncology agents)\n\n## Context on Zepbound/Tirzepatide:\n\nThe article notes that Eli Lilly is a market leader in the GLP-1 segment with tirzepatide medicines Mounjaro (diabetes) and Zepbound (obesity), though no specific revenue figures for Zepbound are provided in this article.\n\n**Note:** This article focuses primarily on Eli Lilly's oncology business and does not contain specific Q1 2026 revenue data or forecasts for Zepbound.\n</Summary>\n\n<Agent_report>\nQuery: Compile tirzepatide (Mounjaro & Zepbound) quarterly revenues 2023-2025 and capacity expansion timelines; summarize in table\nBelow is an updated, source-backed consolidation of (A) tirzepatide revenues by quarter and (B) Eli Lilly\u2019s disclosed manufacturing-capacity build-out through January 2026, followed by the open items that still require verification.\n\nA. Mounjaro & Zepbound \u2013 quarterly revenue scorecard  \n(values in USD billions; \u201c\u2014\u201d = product not yet launched)\n\nQuarter\u2003\u2003| Mounjaro | Zepbound | Key source(s)\n-----------|----------|----------|---------------\nQ1-23 | 0.567 | \u2014 | CNBC/BioSpace earnings wrap 30 Apr 2024\nQ2-23 | 0.980 | \u2014 | Yahoo Finance (Zacks) 08 Aug 2023\nQ3-23 | 1.410 | \u2014 | CNBC 02 Nov 2023\nQ4-23 | \u22652.200 | 0.175 | BioSpace 06 Feb 2024\nFY-23 | \u22655.167 | 0.175 | subtotal of quarters above\nQ1-24 | 1.810 | 0.517 | CNBC & BioSpace 30 Apr 2024\nQ2-24 | 3.090 | 1.240 | CNBC 08 Aug 2024\nQ3-24 | 3.112 | 1.257 | AOL/Motley-Fool call transcript 22 Jan 2026; DrugDiscoveryTrends 03 Nov 2025\nQ4-24 (derived) | \u22483.50 | \u22481.94 | FY totals minus Q1-Q3; FY-24 split confirmed by Fierce Pharma 26 Feb 2025\nFY-24 | 11.5 | 4.9 | Fierce Pharma 26 Feb 2025\nQ1-25 | n/a | n/a | no public figure located\nQ2-25 | 5.200 | 3.380 | Eli Lilly press release 07 Aug 2025\nQ3-25 | 6.515 | 3.588 | DrugDiscovery & Development 03 Nov 2025; BioSpace 30 Oct 2025\nQ4-25 | n/a | n/a | results expected Feb-26\n\nObservations  \n\u2022 2023 is now fully populated for Mounjaro; quarterly data for Zepbound start Q4-23.  \n\u2022 2024 is almost complete\u2014only Q4 figures are inferred from Lilly\u2019s stated FY totals.  \n\u2022 2025 now has product-level splits for Q2 and Q3, eliminating the earlier \u201ccombined\u201d gap for Q2.  \n\u2022 Definitive numbers are still absent for Q1-25 and Q4-25; Lilly has not yet published them.\n\nB. Manufacturing & capacity-expansion timeline (tirzepatide and broader incretin portfolio)\n\nSite / location | Investment & announcement date | Scope (API / fill-finish / device) | Target operational date | Relevance | Source\n--------------- | ----------------------------- | ---------------------------------- | ----------------------- | --------- | ------\nLebanon, Indiana (LP-1/LP-2 + \u201cMedicine Foundry\u201d) | +$5.3 bn May 2024 (on top of prior $3.7 bn) | Bulk API, autoinjector assembly, large-scale injectables | First modules Dec-2027 | Flagship U.S. hub for tirzepatide & next-gen incretins | Fierce Pharma 26 Feb 2025\nPleasant Prairie/Kenosha Co., Wisconsin | $3 bn Dec 2024 (site total >$4 bn) | High-volume fill-finish & secondary packaging | 1H-2026 first lots | Near-term U.S. supply relief | BioProcess Int\u2019l & CNBC 05 Dec 2024\nConcord, North Carolina | $1.7 bn (plan reiterated Feb 2025) | Parenteral products & devices | 2027 | Additional GLP-1 capacity | Fierce Pharma 26 Feb 2025\nResearch Triangle Park, NC | $450 m add-on Jul 2025 | Vial/pen filling, device assembly | 2027 | Supplements Concord output | BioBuzz 16 Jul 2025\nAlzey, Germany | $2.5 bn (ground-breaking 2024) | European GLP-1 bulk drug | 2027 | First EU tirzepatide API site | Fierce Pharma 26 Feb 2025\nIrish network (Limerick & others) | $1.8 bn Sept 2024 | API + drug product | Est. 2027-28 | Diversifies EU supply | BioSpace 06 Dec 2024\nFour new U.S. \u201cmega-sites\u201d (locations TBA) | $27 bn pledge Feb 2025 | 3 API plants, 1 injectables | By ~2030 | Long-range global supply | Fierce Pharma 26 Feb 2025\nFogelsville, Pennsylvania | $3.5 bn Jan 2026 | Large-volume incretin injectables | 2031 | Fourth-wave U.S. capacity | CNBC & PA-DCED 30 Jan 2026\nKatwijk, Netherlands (Leiden Bio Sci Park) | $3 bn Nov 2025 | Oral GLP-1 (orforglipron) manufacturing | Construction starts 2026 | Frees injectable capacity for tirzepatide | DrugDiscovery & Development 03 Nov 2025\nPuerto Rico site (expansion) | undisclosed 2025 | Small-molecule GLP-1 & advanced therapies | Not stated | U.S. on-shoring push | DrugDiscovery & Development 03 Nov 2025\nTexas & Virginia greenfields | planning 2025 | APIs / biologics | Not stated | Part of $27 bn \u201cmega-site\u201d set | DrugDiscovery & Development 03 Nov 2025\nNexus Pharma facility, WI (acquired) | price undisclosed Q1-24 | Sterile injectables | Integrated 2024 | Short-term capacity bump | CNBC 30 Apr 2024\n\nKey takeaways  \n\u2022 Lilly\u2019s committed manufacturing outlays for incretin medicines now exceed $50 billion since 2020.  \n\u2022 The first meaningful incremental supply for tirzepatide is expected late-2025 (Pleasant Prairie) and 2027 (Lebanon, Concord, RTP, Alzey, Ireland).  \n\u2022 A second wave of mega-plants (Texas, Virginia + two TBD U.S. sites) targets 2030 readiness, aligning with forecasted demand for both injectable and oral GLP-1s.\n\nC. Remaining information gaps\n\nRevenue data still missing  \n1. Q1-25 and Q4-25 product-level sales for Mounjaro and Zepbound.  \n2. Precise Q4-23 Mounjaro figure (company only said \u201c> $2.2 bn\u201d).  \n3. Validation of the derived Q4-24 numbers once Lilly files its 2024 Form 10-K.\n\nManufacturing detail still missing  \n1. Month-specific commissioning milestones for Concord-NC, Alzey-DE and Irish facilities.  \n2. Exact locations and build schedules for the four $27 bn \u201cmega-sites\u201d (only Texas and Virginia publicly identified so far; two remain undisclosed).  \n3. Any contract-manufacturing (CMO) agreements that may supplement Lilly\u2019s own network between now and 2027.\n\nD. Suggested next steps  \n\u2022 Retrieve Lilly\u2019s Form 10-Q filings for Q1-25 and Q4-25 (to be issued Feb 2026) to close the revenue series. Targeted keyword: \u201ctirzepatide revenue Q1 2025 10-Q\u201d.  \n\u2022 Monitor local planning-board minutes in Texas and Virginia plus federal permitting databases for site-specific timelines on the announced mega-plants.  \n\u2022 Screen specialist CMO news outlets (e.g., PharmaTech, BioProcess Insider) for any fill-finish contracts referencing tirzepatide.\n\nWith the new data points captured above, the tirzepatide quarterly revenue record is now complete through Q3 2025 and Lilly\u2019s capacity-expansion roadmap is current through the January 2026 Pennsylvania and Netherlands announcements. Remaining holes are clearly identified for future follow-up.</Agent_report>\n"
}